title: Somatotropic adenomas without acromegaly.
abstract: Seventeen somatotropic adenomas removed from patients without acromegaly were studied. Thirteen of them presented as a prolactinoma with amenorrhea and/or galactorrhea and elevated serum PRL levels. According to basal serum GH levels, the patients were divided into two groups, namely Group I: GH slightly elevated (n = 4) and group II: GH less than or equal to 5 micrograms/l (n = 13). The tumoral GH secretion was proved by immunocytochemistry in all cases and by intratumoral RIA, in vitro study and/or in situ hybridization in five of them. Pathological, clinical and biochemical relationships suggested two anatomoclinical aspects. In group I, the tumors were small, well-differentiated somatotropic adenomas with clinically silent GH hypersecretion. It is probably an early stage of the disease. In group II, the tumors were large with normal GH serum levels. They were poorly differentiated and secreted very low amounts of GH. In nine of them, PRL and/or PRL mRNA expression were also detected. These tumors do not secrete enough GH to increase serum levels and cause acromegaly. The somatotropic adenomas without acromegaly correspond to two anatomoclinical aspects of the disease.
authors.affiliation: Laboratoire d'Histologie-Embryologie, Faculté de Médecine Alexis Carrel, Lyon, France.
authors.forename: J
authors.initials: J
authors.lastname: Trouillas
authors.forename: G
authors.initials: G
authors.lastname: Sassolas
authors.forename: B
authors.initials: B
authors.lastname: Loras
authors.forename: B
authors.initials: B
authors.lastname: Velkeniers
authors.forename: M
authors.initials: M
authors.lastname: Raccurt
authors.forename: L
authors.initials: L
authors.lastname: Chotard
authors.forename: F
authors.initials: F
authors.lastname: Berthezène
authors.forename: J
authors.initials: J
authors.lastname: Tourniaire
authors.forename: C
authors.initials: C
authors.lastname: Girod
mesh_terms: D000172:Acromegaly / Q000150:complications* / Q000175:diagnosis / Q000473:pathology; D000236:Adenoma / Q000150:complications* / Q000175:diagnosis / Q000473:pathology; D000293:Adolescent; D000328:Adult; D000568:Amenorrhea / Q000150:complications / Q000175:diagnosis / Q000473:pathology; D004273:DNA, Neoplasm / Q000235:genetics; D005260:Female; D013006:Growth Hormone / Q000097:blood / Q000235:genetics; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D009693:Nucleic Acid Hybridization; D010911:Pituitary Neoplasms / Q000150:complications* / Q000175:diagnosis / Q000473:pathology; D011388:Prolactin / Q000097:blood / Q000235:genetics; D015175:Prolactinoma / Q000150:complications / Q000175:diagnosis / Q000473:pathology; D012333:RNA, Messenger / Q000032:analysis / Q000235:genetics; D011863:Radioimmunoassay
chemical_list: D004273:DNA, Neoplasm; D012333:RNA, Messenger; D011388:Prolactin; D013006:Growth Hormone